followed by injection of bovine TSH before the application of 150 μCi (5.5 MBq) 131 I decreased serum T 4 concentrations below the detection limit and significantly increased pituitary TSHβ concentrations. The systemic effects of induced hypothyroidism were shown by growth arrest and a decrease in liver DIO1 expression below the detection limit. 99m Tc-pertechnetate scintigraphy revealed absence of thyroidal 99m Tc-pertechnetate uptake in ablated mice. In summary, we report a revised protocol for radioiodide ablation of the thyroid gland in the mouse to generate an in vivo model that allows the study of thyroid hormone action using NIS as a reporter gene.
Introduction
Mouse models of hypothyroidism increase our understanding of the mechanisms that regulate thyroid hormone action both during normal function and disease.
Drug-induced hypothyroidism is a commonly used approach for assessment of thyroid hormone action in rodent models. An alternative approach makes use of the thyroid-lethal properties of the radionuclide iodide-131 ( 131 I) to induce hypothyroidism. This is based on the ability of thyroid follicular cells to transport and concentrate radioactive iodide due to their expression of the sodium iodide symporter (NIS). Several nonthyroidal organs physiologically express NIS, such as salivary glands, gastric mucosa and lactating mammary glands, and therefore possess the ability to actively transport iodide. They do not, however, organify and store it. These characteristics allow for high thyroid-specific cytotoxicity of 131 I with minimal side effects [1] .
The first report of selective destruction of thyroid tissue by 131 I was published by Hamilton [2] in 1942. Since then, numerous protocols for radioiodide ablation of the mouse thyroid gland have been published with broad variation of the thyroid-lethal dose of 131 I administered to mice ranging from 28 to 1,000 μCi (1-37 MBq) in the presence or absence of stimulation of thyroidal iodide uptake by treatment with a low-iodine diet (LID) for 1-4 weeks or exogenous thyroid-stimulating hormone (TSH) application prior to the administration of radioiodide [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] .
We and others have shown the potential of NIS as a reporter gene for molecular imaging with a broad range of possible applications [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] . In our previous work, the role of NIS as a reporter gene allowed noninvasive multimodal imaging of functional NIS expression by I PET imaging that correlated well with the results of ex vivo gamma counter measurements as well as NIS mRNA and protein analysis. Stem cells have been the focus of research in gene and cellular therapies. To date, these studies have lacked detailed information about the exact in vivo biodistribution, survival and biological compartment of these cells in tissues. Genetically engineered mesenchymal stem cells that express NIS allow detailed noninvasive in vivo tracking of stem cells from their initial deposition to survival, migration and differentiation by 123 I scintigraphy/SPECT and 124 I PET, as demonstrated in our previous work [17, 18] .
Based on these studies, we are now employing this system to study thyroid hormone action on mesenchymal stem cell biology within the tumor microenvironment. In an effort to generate a thyroid-ablated mouse model for the NIS-based evaluation of thyroid hormone action avoiding interference with thyroidal NIS that underlies an exclusive regulation by TSH, in the current study we describe an effective protocol for thyroid radioiodide ablation in mice.
Materials and Methods

Animals
Male CD1 nu/nu mice from Charles River (Sulzfeld, Germany) were maintained under specific pathogen-free conditions with access to a standard nude mouse diet (2.2 mg/kg iodine; ssniff, Soest, Germany) or LID (<15 μg/kg iodine; ssniff) and tap water ad libitum. Animals were allowed to acclimatize for 1 week prior to the start of treatments. At the beginning of the experiments, mice weighed 25-30 g with an average body weight of 26.6 ± 1.27 g (mean ± SD). At the end of the experiments, animals were sacrificed and tissues and blood were taken for analysis. The experimental protocol was approved by the regional governmental commission for animals (Regierung von Oberbayern, Munich, Germany).
Thyroid Radioiodide Ablation
Mice were randomly assigned to different treatment groups. For thyroid ablation, animals received a single i.p. injection of 200 μCi (7.4 MBq; according to Kasuga et al. [10] ; n = 6), 500 μCi (18.5 MBq; according to Gorbman [3] ; n = 6) or 150 μCi (5.5 MBq; according to Abel et al. [11] and Barca-Mayo et al. [12] ; n = 12) of carrier-free 131 I in 250 μl of phosphate-buffered saline containing sodium thiosulfate as a reducing agent (GE Healthcare, Braunschweig, Germany) or saline for control animals (n = 6 for each experiment). Animals that received 500 μCi of 131 I were additionally put on LID 1 week prior to radioiodide application. Before administration of the 150 μCi of 131 I, mice were fed LID for 1 week and on day 8 received an i.p. injection of 10 mIU of bovine TSH (Sigma, Munich, Germany) 2 h before radioiodide application. A subset of radioiodide-ablated animals (n = 6) received daily i.p. injections of 20 ng/g body weight T 4 (Sigma) starting the day after the application of 131 I.
Serum T 4 Measurements
T 4 concentrations were monitored in pooled serum samples from tail vein blood or in individual serum samples after sacrifice. Serum total T 4 concentrations were measured in duplicate by radioimmunoassay using a commercially available kit (RIA-4524; DRG Instruments, Marburg, Germany) according to the manufacturer's instructions. The samples and calibrators were incubated with radiolabelled tracer in antibody-coated tubes. After incubation, the liquid was aspirated and the antibody-bound radiolabelled tracer was counted in a gamma counter (1277 GammaMaster; LKB Wallac, Turku, Finland). The limit of quantification was at 10 n M with an intra-assay coefficient of variation of 3.6% at 80 n M and 1.1% at 167 n M .
Whole-Body Planar 99m
Tc-Pertechnetate Scintigraphy Two hours after i.p. injection of 500 μCi (18.5 MBq) of 99m Tcpertechnetate, a gamma emitter that is also transported by NIS [24] , 99m Tc-pertechnetate accumulation was assessed using a gamma camera equipped with a low-energy high-resolution collimator (e.cam, Siemens, Munich, Germany). Imaging studies were performed under inhalational anesthesia using an isoflurane vaporizer. Regions of interest were quantified and expressed as a fraction of the injected dose of applied radionuclide in the cervical region. 76 was prepared using the RNeasy Mini Kit with QIAshredder (Qiagen, Hilden, Germany) according to the manufacturer's instructions. Reverse transcription was performed using SuperScript III First-Strand Synthesis System (Invitrogen Life Technologies, Karlsruhe, Germany). Quantitative real-time PCR was run in duplicate with the QuantiTect SYBR Green PCR Kit (Qiagen) in a Mastercycler ep gradient S PCR cycler (Eppendorf, Hamburg, Germany). Relative expression levels of pituitary TSHβ and liver deiodinase type 1 (DIO1) were calculated from ΔΔC t values normalized to internal β-actin and 18S rRNA. The following primers were used:
RNA Extraction and Quantitative Real-Time PCR
Actb , forward 5 ′ -AAGAGCTATGAGCTGCCTGA-3 ′ , reverse 5 ′ -TACGGATGTCAACGTCACAC-3 ′ ; R18s , forward 5 ′ -CGCAGCTAGGAATAATGGAA-3 ′ , reverse 5 ′ -TCTGATC- GTCTTCGAACCTC-3 ′ ; Tshb , forward 5 ′ -GGGTATTGTAT- GACACGGGATA-3 ′ , reverse 5 ′ -ATTTCCACCGTTCTGTAG- ATGA-3 ′ ; Dio1 , forward 5 ′ -AAGACAGGGCTGAGTTTGGG-3 ′ , reverse 5 ′ -TGAGGAAATCGGCTGTGGAG-3 ′ .
Statistical Analysis
Every data point was generated using 3-6 mice per group. Values are reported as means ± SEM or mean fold change ± SEM. Statistical significance of T 4 and TSHβ concentrations were tested by two-tailed Student's t tests, and statistical significance of body weight measurements was tested by a two-tailed Mann-Whitney U test ( * p < 0.05; * * p < 0.01; * * * p < 0.001).
Results
I Ablation and T 4 Measurements
Three different protocols for radioiodide ablation of the thyroid gland were compared with the aim of establishing a thyroid-ablated mouse model of hypothyroidism. Four weeks after administration of a single dose of 200 μCi of 131 I, serum T 4 concentrations had dropped by 50% in ablated mice compared to untreated control animals ( fig. 1 a) .
By increasing the 131 I dose to 500 μCi with additional treatment with LID for 1 week prior to 131 I application, serum T 4 concentrations dropped below the limit of detection (<10 n M ) as early as 2 weeks after radioiodide administration ( fig. 1 a) . However, starting at approximately 1 week after ablation, mice suffered from drastic weight loss and heavy breathing despite T 4 supplementation in a subgroup of mice, and, as a result, had to be sacrificed ( fig. 1 b) .
The 77 that remained stable until the end of the observation period (10 weeks after ablation; fig. 1 c) . The ablated mice without T 4 supplementation showed only minor side effects such as absence of weight gain ( fig. 3 ) and slower movement in the cage. Therefore, all further experiments were conducted following this protocol. Serum T 4 concentrations in the subgroup of mice that received T 4 supplementation by daily i.p. injections of 20 ng of T 4 per gram body weight were in the same range as in the untreated euthyroid group of mice ( fig. 1 c) .
Monitoring of Body Weight and Analysis of TSHβ and DIO1 mRNA Expression
The drop in serum T 4 concentrations in ablated mice coincided with a 48-and 45-fold increase, respectively, in pituitary TSHβ concentrations 2 and 10 weeks after thyroid ablation, compared to untreated controls ( fig. 2 ) .
As a drop in serum T 4 and elevation of pituitary TSH do not per se prove a systemic state of hypothyroidism, we additionally monitored body weight gain in ablated mice versus untreated control mice. Radioiodide-ablated mice showed an arrest in growth from around 1 week after 131 I injection, while untreated control animals continued to grow throughout the observation period ( fig. 3 ) . We also investigated expression of DIO1 in the liver as a second marker for systemic hypothyroidism. Four weeks after 131 I application, liver DIO1 mRNA concentrations dropped below the detection limit with C t values >40, whereas for control animals a mean C t value of 26.11 ± 0.69 was measured with comparable reference gene concentrations between the two treatment groups.
99m Tc-Pertechnetate Whole-Body Imaging
To examine the effects of 131 I ablation on thyroidal radioiodide uptake, we monitored 99m Tc-pertechnetate biodistribution by gamma camera imaging. Significant 99m Tc-pertechnetate accumulation was observed in tissues that physiologically express NIS, i.e. thyroid, salivary glands and stomach, as well as the urinary bladder due to renal elimination of the radionuclide ( fig. 4 ) . Four weeks after 131 I injection, 99m Tc-pertechnetate uptake was strongly reduced in the cervical region of ablated mice with a remaining 99m Tc-pertechnetate uptake of approximately 3-5%, which was caused by the salivary glands that in mice are localized in the direct neighborhood of the thyroid gland and physiologically express NIS ( fig. 4 a) [25] . In comparison, untreated control mice accumulated approximately 35-40% of the injected dose in the cervical region ( fig. 4 b) .
Discussion
The aim of the current study was to generate a mouse model in which endogenous thyroid hormone production is abolished to create an experimental paradigm with 78 a defined baseline for the evaluation of response to thyroid hormone that at the same time allows for the use of NIS as a reporter gene. While treatment of mice with antithyroid drugs in drinking water is a widely used approach to render mice hypothyroid, mice have to be treated throughout the experiment, a certain degree of variability remains due to differences in water intake and potential side effects of the drugs have to be taken into consideration [26, 27] . Furthermore, as this approach typically relies on a combination of thioamides (methimazole or propylthiouracil) that have been shown to affect thyroidal NIS expression [28] , as well as the NIS-specific inhibitor perchlorate to block thyroid hormone synthesis, the use of NIS as a reporter gene to study thyroid hormone action is limited in this setting.
For these reasons, a reliable method of thyroid radioiodide ablation was developed in mice that exploits the ability of NIS to transport 131 I. This eliminates interference of reporter gene activity from thyroidal NIS that is exclusively regulated by TSH and therefore affected by the thyroid hormone status of the mouse. A literature search revealed a variety of protocols [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] . As the 'American Thyroid Association Guide to investigating thyroid hormone economy and action in rodent and cell models' [29] had just been published, we initially tested the protocol described there [10] . Here the recommended 131 I dose of 200 μCi was not sufficient to completely abolish endogenous thyroid hormone production. This was most likely due to insufficient accumulation of radioiodide in the thyroid, as mice were fed standard chow containing 2.2 mg/kg iodine, which competes with radioiodide for thyroidal uptake. We therefore increased the amount of 131 I to 500 μCi, a dose that was reported by Gorbman [3] to destroy thyroid tissue within 24 days after radioiodide application. In addition, we pretreated mice with LID for 1 week prior to 131 I application to decrease thyroidal iodine content and increase thyroidal NIS expression to enhance the uptake of radioiodide into thyroid follicular cells. This treatment decreased serum T 4 concentrations below the detection limit. However, mice showed severe side effects, i.e. drastic weight loss and breathing difficulties, starting from around 1 week after iodide injection irrespective of T 4 supplementation, and had to be sacrificed prematurely. We assume that the relatively high dose of 131 I, while specifically concentrated in the thyroid, caused severe damage to the thyroid-surrounding tissues, in particular the radiation-sensitive trachea. Due to the close proximity of these tissues to the thyroid and the thyroid's small size, the β-particles emitted by 131 I that have a path length of up to 2.4 mm in tissue [30] can cause lesions in the trachea, recurrent laryngeal nerve and parathyroid glands, as was observed by Gorbman [4] . Furthermore, transient NIS-mediated transport of high doses of radioiodide across epithelia in the gastrointestinal tract may impair their function and lead to subsequent damage.
To avoid the aforementioned problems, we adapted protocols published by Abel et al. [11] and Barca-Mayo et al. [12] , where relatively low doses of 131 I were reported to be sufficient for total ablation of the thyroid gland under stimulation of 131 I uptake. We decided on a protocol consisting of 1 week of LID, followed by an injection of bovine TSH on day 8, 2 h before injection of 150 μCi of 131 I. We showed the efficacy of this protocol in inducing hypothyroidism in mice at the level of (1) the first indicators of a disruption of thyroid function, i.e. serum T 4 concentrations and pituitary TSHβ content, (2) indicators of systemic hypothyroidism, i.e. growth arrest and decrease in liver DIO1 concentrations, and (3) the thyroid itself by 99m Tc-pertechnetate gamma camera imaging. Two weeks after thyroid ablation, serum T 4 concentrations had dropped below the detection limit and, as expected, pituitary TSHβ concentrations reactively increased 48-fold compared to untreated control mice. At the end of the observation period, 10 weeks after thyroid ablation, T 4 concentrations remained undetectable and TSHβ concentrations remained high. As growth hormone secretion is thyroid hormone sensitive in rodents [31] , ablated mice showed an arrest in growth as a consequence of decreasing serum thyroid hormone concentrations, indicating systemic hypothyroidism. Another marker for systemic thyroid hormone status is liver DIO1, which is downregulated in hypothyroidism [32] . Four weeks after thyroid ablation, liver DIO1 mRNA concentrations had dropped below the detection limit. Gamma camera imaging revealed a significant reduction in 99m Tcpertechnetate uptake in the cervical region 4 weeks after thyroid ablation, despite maximal TSH stimulation due to thyroid hormone deficiency in ablated animals. The low residual uptake originates from salivary glands that also physiologically express NIS [25, 33] . In mice, the submandibular-sublingual salivary gland complex is relatively large in relation to the thyroid and is located in the ventral cervical region in the direct neighborhood of the thyroid, therefore causing an overlapping signal on 123 I or 99m
Tc-pertechnetate scintigraphies [34] . As salivary glands do not possess the ability to organify iodine, retention time of the thyroid-ablative dose of 131 I is limited. Thus, salivary glands are preserved, at least in part, as is their ability to accumulate 99m Tc-pertechnetate, while thyroidal uptake is completely eliminated, as was shown by whole-body and neck transaxial planar SPECT imaging by Choi et al. [35] .
In conclusion, our data provide an effective protocol for radioiodide ablation of the thyroid gland that renders mice hypothyroid within the course of 2 weeks and abolishes thyroidal radioiodide uptake. Based on our findings, we recommend stimulation of NIS-mediated thyroidal iodide uptake by pretreatment with LID and TSH application to help deliver a well-tolerated dose of 150 μCi of 131 I to mice for successful ablation of the thyroid gland.
